A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile.
Ontology highlight
ABSTRACT: Prostate-specific membrane antigen (PSMA) is a promising target for the treatment of advanced prostate cancer (PC) and various solid tumors. Although PSMA-targeted radiopharmaceutical therapy (RPT) has enabled significant imaging and prostate-specific antigen (PSA) responses, accumulating clinical data are beginning to reveal certain limitations, including a subgroup of non-responders, relapse, radiation-induced toxicity, and the need for specialized facilities for its administration. To date non-radioactive attempts to leverage PSMA to treat PC with antibodies, nanomedicines or cell-based therapies have met with modest success. We developed a non-radioactive prodrug, SBPD-1, composed of a small-molecule PSMA-targeting moiety, a cancer-selective cleavable linker, and the microtubule inhibi
SUBMITTER: Boinapally S
PROVIDER: S-EPMC8007718 | biostudies-literature | 2021 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA